Affordable Access

Publisher Website

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance

Authors
Journal
European Journal of Cancer
0959-8049
Publisher
Elsevier
Publication Date
Volume
28
Identifiers
DOI: 10.1016/0959-8049(92)90119-m

Abstract

Abstract In vitro tamoxifen reverses multidrug resistance (MDR). To evaluate the clinical potential of using tamoxifen in this way, intermittent high-dose tamoxifen was combined with oral etoposide in 86 patients. At 320 mg/day tamoxifen for 6 days, mean plasma levels of tamoxifen in 11 patients increased from 453 ng/ml (range 269–664) on day 2 to 984 ng/ml (578–1336) on day 6. Of 31 patients who had plasma tamoxifen measured during the time of etoposide administration (days 4–6), 13 (43%) were over 1111 ng/ml (3 μmol/l), an active in vitro level. Potentially active levels of the principal metabolite, N-desmethyl tamoxifen, were also obtained but accumulation was slower. Emesis and thromboembolism were toxicities. Tamoxifen is a modifier of MDR, a role that warrants further clinical studies.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

High-dose oral tamoxifen, a potential multidrug-re...

on JNCI Journal of the National C... Dec 02, 1992

A phase I/II trial of epirubicin and high dose tam...

on European Journal of Cancer December 1996

Treatment of advanced colorectal cancer with doxor...

on Journal of cancer research and... 1997
More articles like this..